The historical data trend for Ipca Laboratories's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:IPCALAB vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipca Laboratories Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Ipca Laboratories's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipca Laboratories (NSE:IPCALAB) has a Buyback Yield % of 0.00 as of Jul. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Ipca Laboratories and its competitors. According to the industry distribution chart, Ipca Laboratories ranks #999999 out of 291 companies in the Drug Manufacturers industry.
Is Ipca Laboratories' Buyback Yield % too high?
Ipca Laboratories' current Buyback Yield % is 0.00. Based on the distribution chart, Ipca Laboratories ranks #999999 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ipca Laboratories has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipca Laboratories ranks #999999 out of 291 companies for Buyback Yield %. This places Ipca Laboratories in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Ipca Laboratories and its competitors. Ipca Laboratories's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,600.85, compared to a current price of ₹1,793.10 — trading 12% above its estimated fair value. The current Buyback Yield % is 0.00. Ipca Laboratories' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current Buyback Yield % is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued.
The current stock price of ₹1,793.10 is trading 12% above its estimated GF Value™ of ₹1,600.85.
GuruFocus considers Ipca Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:IPCALAB:
Buyback Yield %: 0.00
GF Value™: ₹1,600.85 vs. price of ₹1,793.10 (12% above fair value)
No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
91GF Score
Get the complete analysis for NSE:IPCALAB
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IPCALAB has been successfully added to your 
